Xalkori® (crizotinib) – New indication
January 14, 2021 - Pfizer announced the FDA approval of Xalkori (crizotinib), for the treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive.
Top